![Carole Nüchterlein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Carole Nüchterlein
Directeur/Membre du Conseil chez
ALIGOS THERAPEUTICS, INC.
Fortune : - $ au 31/05/2026
Profil
Carole L.
Nüchterlein currently serves as Deputy Director & Head-Roche Venture Fund at F.
Hoffmann-La Roche Ltd. since 2002.
Also holds the position of Deputy Director & Head at Roche Venture Fund, Head of Roche Venture Fund at Roche Ventures since 2002, and Director roles at Second Genome, Inc. (since 2016), MISSION Therapeutics Ltd. (since 2017), Lumos Pharma Sub, Inc. (since 2017), CiVi Biopharma, Inc. (since 2017), Vivet Therapeutics SAS (since 2017), CiVi Biopharma Holdings, Inc., Aligos Therapeutics, Inc. (Independent Director since 2018), and Enthera Srl.
Former roles include Director positions at Ambit Biosciences Corp., Pharmasset, Inc., Alios BioPharma, Inc., MacuLogix, Inc., Envoy Therapeutics, Inc., Allakos, Inc., Lysosomal Therapeutics, Inc., Arch Oncology, Inc., and Independent Director at Novartis Gene Therapies, Inc. (2014–2017), Millendo Therapeutics, Inc. (2017–2021), Entrada Therapeutics, Inc. (2020–2023), Director at Millendo Therapeutics US, Inc. (2017–2021), Independent Director at BCTG Acquisition Corp.
(2020–2021), and General Counsel at SangStat Medical Corp.
(1998–2001).
Education includes graduate studies at the University of Michigan and undergraduate studies at Valparaiso University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Carole Nüchterlein
| Sociétés | Poste | Début |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2018 |
Roche Ventures
 Roche Ventures Investment ManagersFinance Roche Ventures invests in companies located in Switzerland and the United States. The firm focuses on pharmaceuticals, diagnostics and digital health. It participates in early stage capital transactions with an investment size of CHF 3 - 10 million. It acquires minority stakes and also makes follow-on financing. | Private Equity Investor | 01/01/2002 |
CiVi Biopharma, Inc.
 CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which manufactures novel therapies against cardiovascular and metabolic diseases | Directeur/Membre du Conseil | 01/03/2017 |
CiVi Biopharma Holdings, Inc.
 CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage research and development biotechnology company | Directeur/Membre du Conseil | - |
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Directeur/Membre du Conseil | 01/04/2016 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Directeur/Membre du Conseil | 01/01/2017 |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Operates as a clinical-stage emerging biotechnology company that develops novel gene therapy treatments for rare and inherited metabolic diseases | Directeur/Membre du Conseil | 01/04/2017 |
MISSION Therapeutics Ltd.
 MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs targeting enzymes involved in cancer and other diseases | Directeur/Membre du Conseil | 01/01/2017 |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/01/2002 |
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Anciens postes connus de Carole Nüchterlein
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Carole Nüchterlein
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
26
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 26 |
|---|---|
SangStat Medical Corp.
 SangStat Medical Corp. Pharmaceuticals: MajorHealth Technology Develops therapeutic and monitoring products to improve the outcome of organ transplantation | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Develops and sells molecule kinase inhibitors for the treatment of cancer | Health Technology |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Develops drugs to treat viral infections | Health Technology |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
Millendo Therapeutics US, Inc.
 Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company which develops a novel treatment for adrenal cancer | Health Technology |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Valparaiso University
 Valparaiso University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Ventures
Roche Ventures Investment ManagersFinance Roche Ventures invests in companies located in Switzerland and the United States. The firm focuses on pharmaceuticals, diagnostics and digital health. It participates in early stage capital transactions with an investment size of CHF 3 - 10 million. It acquires minority stakes and also makes follow-on financing. | Finance |
MacuLogix, Inc.
 MacuLogix, Inc. Medical/Nursing ServicesHealth Services Engages in diagnosis of dry age-related macular degeneration patients | Health Services |
Envoy Therapeutics, Inc.
 Envoy Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for treatment of neurological and psychiatric diseases | Health Technology |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Arch Oncology, Inc.
 Arch Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company that develops biologic therapies for treatment of patients with tumors and hematologic malignancies | Health Technology |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs targeting enzymes involved in cancer and other diseases | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
Allakos, Inc.
 Allakos, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biotechnology company that develops innovative therapeutics which target immunomodulatory receptors for the treatment of allergic, inflammatory and proliferative diseases | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage gene therapy company | Health Technology |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecules for use in the treatment of neurodegenerative diseases | Health Technology |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which manufactures novel therapies against cardiovascular and metabolic diseases | Health Technology |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Operates as a clinical-stage emerging biotechnology company that develops novel gene therapy treatments for rare and inherited metabolic diseases | Health Technology |
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage research and development biotechnology company | Commercial Services |
Enthera Srl
 Enthera Srl BiotechnologyHealth Technology Operates as a biotech manufacturing company that develops biotherapeutics treatments for underserved auto-immune disorders | Health Technology |
Millendo Therapeutics, Inc.
 Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Entrada Therapeutics, Inc.
 Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Aligos Therapeutics, Inc.
 Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
BCTG Acquisition Corp.
 BCTG Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
